Invest in Israel Newsletter August 2010 Edition
VC Cafe
AUGUST 30, 2010
Medical product giant Baxter International and Israeli biopharmaceutical company Kamada entered into a definitive distribution agreement for Glassia, the first and only liquid, ready-to-use Alpha1-Proteinase inhibitor that treats genetic lung-damaging disorder alpha-1 antitryspin (AAT). Canada, Australia and New Zealand.
Let's personalize your content